Latest industry research report on Epilepsy is a chronic brain disorder characterized by sudden and recurrent episodes of seizure. It is one of the most common neurological disorders worldwide, affecting people of all ages. Presently, around 50 million patients are living with epilepsy worldwide and about 2.4 million new cases are diagnosed annually. Moreover, majority of the epileptic cases are idiopathic, with no identifiable cause. At present, only symptomatic treatment through medication, surgery and implantable devices, is available, but there is no cure for epilepsy. This highlights the untapped market need for better therapeutics which would provide lucrative growth opportunities to industry players.
Rising incidence of neurological disorders, higher incidence of birth related injuries, increasing road traffic injuries, growing disease awareness and rising patient base in developing countries, are the significant factors driving the global antiepileptic drug market.
Get Free Sample Report Of Epilepsy Market @ http://www.marketresearchstore.com/report/world-epilepsy-drug-market-opportunities-and-forecasts-71723#RequestSample
Moreover, increasing R&D investment and launch of extended-release formulations are further expected to fuel the market growth. However, high cost of patented drugs and low accessibility to antiepileptic drugs in low and middle income countries, are likely to restrict the market growth.
Collaboration and new product approval are some of the key strategies adopted by leading industry players. In July 2014, Intellimedix entered into research collaboration with Pfizer and The Epilepsy Foundation, for preclinical testing of an experimental drug. Sunovion Pharmaceuticals Inc., in Nov 2013, got FDA marketing approval for epilepsy drug Aptiom (eslicarbazepine acetate) for treatment of partial seizures.
Do Inquiry To Buy Report Of Epilepsy Market @ http://www.marketresearchstore.com/report/world-epilepsy-drug-market-opportunities-and-forecasts-71723#InquiryForBuying
The global Epilepsy Drug market is segmented below:
Epilepsy Drug Market By Drug Type
First Generation Drugs